0001079973-21-000365.txt : 20210513 0001079973-21-000365.hdr.sgml : 20210513 20210512211517 ACCESSION NUMBER: 0001079973-21-000365 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210512 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210513 DATE AS OF CHANGE: 20210512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifeloc Technologies, Inc CENTRAL INDEX KEY: 0001493137 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 841053680 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54319 FILM NUMBER: 21916867 BUSINESS ADDRESS: STREET 1: 12441 WEST 49TH AVE UNIT #4 CITY: WHEAT RIDGE STATE: CO ZIP: 80033 BUSINESS PHONE: 303-431-9500 MAIL ADDRESS: STREET 1: 12441 WEST 49TH AVE UNIT #4 CITY: WHEAT RIDGE STATE: CO ZIP: 80033 FORMER COMPANY: FORMER CONFORMED NAME: Lifeloc Technologies Inc DATE OF NAME CHANGE: 20100601 8-K 1 lifeloc_8k-051221.htm FORM 8-K

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 12, 2021

 

LIFELOC TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Colorado   000-54319   84-1053680
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)

 

12441 West 49th Ave., Unit 4    
Wheat Ridge, CO   80033
(Address of Principal Executive Offices)   (Zip Code)

 

(303) 431-9500

(Registrant’s telephone number, including area code)

   

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [_]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_] 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock LCTC N/A

 

 

 

 

 
 
 

 

 

Item 2.02Results of Operations and Financial Condition.

 

On May 12, 2021, Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing its operating results for the first quarter for the three months ended March 31, 2021. This press release was made available on the Company’s website as of May 12, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.

 

The information in this Form 8-K, including the exhibit attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.

 

  Item 9.01 Financial Statements and Exhibits.
     

(d) Exhibits.

   

Exhibit No. Description

 

99.1 Press Release, dated May 12, 2021, issued by the Company

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date:  May 12, 2021 LIFELOC TECHNOLOGIES, INC.
     
  By:   /s/ Vern D. Kornelsen
    Chief Financial Officer and Secretary

 

 

 

EX-99.1 2 lifeloc_ex991.htm EXHIBIT 99.1

Exhibit 99.1

 

Lifeloc Reports First Quarter 2021 Results

WHEAT RIDGE, Colo., May 12, 2020 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2021.

First Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $1.810 million resulting in a quarterly net income of $403 thousand, or $0.16 per diluted share. These results compare to net revenue of $2.018 million and quarterly net loss of $(165) thousand, or $(0.07) per diluted share in the first quarter of 2020. Revenue for the quarter declined 10% versus the first quarter last year, primarily from the impact of the COVID-19 global pandemic and the government ordered shutdowns.

As previously reported in 2020, Lifeloc received a $465 thousand SBA guaranteed loan through the Paycheck Protection Program (PPP). These loans could be completely forgiven by the SBA if the proceeds were spent in accordance with the program rules. Lifeloc complied with this program and applied for forgiveness in 2020, which was granted by the SBA in early 2021, with the financial benefit of the forgiveness realized in the first quarter of 2021. The PPP program was quite successful in mitigating the negative effect of the significant demand suppression on cash flow from the pandemic while allowing Lifeloc to carefully reduce structural costs and retain critical personnel, with no compromise to our product development efforts.

Lifeloc qualified for and received a second PPP loan of $471 thousand in Q1 of 2021. As with the first loan, Lifeloc intends to comply with all requirements and will apply for forgiveness of this loan after the program conditions are satisfied and the application process is made available.

Our new platform LX9 and LT7 devices were introduced late in 2019. Despite current difficult market conditions, the features (and performance) of the new L-series products have driven penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. We expect that most L-series sales will be incremental to FC-series devices rather than displacing FC-series sales. “In January 2021 our L-series devices were certified to SAI’s (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. This achievement solidifies our ability to provide advanced breath alcohol detectors to a robust market and provides a product certification that is highly regarded in the Pacific Rim,” said Mark Lary, Director of Regulatory Affairs.

We continue to invest in the significant growth opportunities of alcohol monitoring and drug detection. The monitoring opportunity will be addressed primarily through the redesigned Real-Time Alcohol Detection and Reporting (R.A.D.A.R.®) device. Manufacture of the second generation R.A.D.A.R. 200 protype devices began in late 2020. Testing of these redesigned R.A.D.A.R. devices and integration with the monitoring system has been extensive, requiring additional modification before final release. The design has been finalized with several devices now in field testing by key customers and sales release planned this year. Several upgrades have been made to the reporting system with an entirely new enrollment app to automate that process.

 
 
 

 

Our most important goal remains the convergence of the market need for rapid detection of drugs of abuse with Lifeloc’s capabilities. Resources have been committed to finalizing the development of the SpinDx™ technology platform and the rapid, quantitative marijuana breathalyzer built on that platform. We have improved the detection sensitivity for delta-9-THC as well as the robustness of the device. Work continues to develop this system into a device that can be used for roadside testing.

“We look forward to the continued improvement of general business conditions, especially within our customer base. The last year has been particularly difficult for the travel industry and law enforcement,” commented Dr. Wayne Willkomm, President and CEO. “But our real growth driver is the strong pipeline of recent and coming product releases. Additional features requested by various European law enforcement agencies are being added to the L-series platform. Together with the imminent release of the redesigned R.A.D.A.R 200 devices, this should develop a healthy recurring revenue stream. The next big milestone for Lifeloc will be completing the commercialization of the SpinDx platform – a major effort that will be prioritized over short-term profitability.”

About Lifeloc Technologies

 

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

 

Forward Looking Statements

 

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

 

R.A.D.A.R.® is a registered trademark of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Amy Evans 
Lifeloc Technologies, Inc. 
http://www.lifeloc.com 
(303) 431-9500

 

 
 
 

 

LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets

ASSETS      
   March 31,   
   2021  December 31,
CURRENT ASSETS:  (Unaudited)  2020
Cash  $2,317,035   $2,195,070 
Accounts receivable, net   693,225    523,603 
Inventories, net   2,580,148    2,498,126 
Income taxes receivable   234,541    220,657 
Prepaid expenses and other   98,568    77,962 
      Total current assets   5,923,517    5,515,418 
           
PROPERTY AND EQUIPMENT, at cost:          
Land   317,932    317,932 
Building   1,928,795    1,928,795 
Real-time Alcohol Detection And Recognition equipment and software   569,448    569,448 
Production equipment, software and space modifications   958,785    958,785 
Training courses   432,375    432,375 
Office equipment, software and space modifications   216,618    216,618 
Sales and marketing equipment and space modifications   226,356    226,356 
Research and development equipment, software and space modifications   190,818    190,818 
Less accumulated depreciation   (2,341,432)   (2,277,839)
     Total property and equipment, net   2,499,695    2,563,288 
           
OTHER ASSETS:          
Patents, net   141,738    144,702 
Deposits and other   164,798    164,798 
Deferred taxes   149,583    148,142 
     Total other assets   456,119    457,642 
           
     Total assets  $8,879,331   $8,536,348 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
CURRENT LIABILITIES:          
Accounts payable  $355,819   $333,851 
Term loan payable, current portion   46,612    46,936 
Paycheck Protection loan payable   471,347    465,097 
Customer deposits   161,465    155,295 
Accrued expenses   163,719    266,266 
Deferred revenue, current portion   44,154    41,053 
Reserve for warranty expense   46,500    46,500 
      Total current liabilities   1,289,616    1,354,998 
           
TERM LOAN PAYABLE, net of current portion and          
debt issuance costs   1,266,120    1,277,531 
           
DEFERRED REVENUE, net of current portion   2,325    3,177 
      Total liabilities   2,558,061    2,635,706 
           
COMMITMENTS AND CONTINGENCIES          
           
STOCKHOLDERS' EQUITY:          
Common stock, no par value; 50,000,000 shares          
  authorized, 2,454,116 shares outstanding   4,650,812    4,633,655 
Retained earnings   1,670,458    1,266,987 
      Total stockholders' equity   6,321,270    5,900,642 
           
      Total liabilities and stockholders' equity  $8,879,331   $8,536,348 

 

 
 
 

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Unaudited)

 
   Three Months Ended March 31,
REVENUES:  2021  2020
Product sales  $1,775,447   $1,937,866 
Royalties   12,564    59,281 
Rental income   21,532    21,189 
Total   1,809,543    2,018,336 
           
COST OF SALES   985,666    1,240,260 
           
GROSS PROFIT   823,877    778,076 
           
OPERATING EXPENSES:          
Research and development   307,212    296,897 
Sales and marketing   230,478    326,564 
General and administrative   350,120    356,887 
Total   887,810    980,348 
           
OPERATING INCOME (LOSS)   (63,933)   (202,272)
           
OTHER INCOME (EXPENSE):          
Forgiveness of Paycheck Protection loan   465,097    —   
Interest income   499    7,176 
Interest expense   (13,517)   (14,131)
Total other income (expense)   452,079    (6,955)
           
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES   388,146    (209,227)
           
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES   15,325    43,921 
           
NET INCOME (LOSS)  $403,471   $(165,306)
           
NET INCOME (LOSS) PER SHARE, BASIC  $0.16   $(0.07)
           
NET INCOME (LOSS) PER SHARE, DILUTED  $0.16   $(0.07)
           
WEIGHTED AVERAGE SHARES, BASIC   2,454,116    2,454,116 
           
WEIGHTED AVERAGE SHARES, DILUTED   2,454,116    2,454,116 

 

 
 
 

Lifeloc Technologies, Inc.
Statements of Stockholders' Equity (Unaudited)

   Three Months Ended March 31,
   2021  2020
Total stockholders' equity, beginning balances  $5,900,642   $6,792,221 
           
Common stock (no shares issued during periods):          
Beginning balances   4,633,655    4,603,304 
Stock based compensation expense related          
 to stock options   17,157    32,111 
Ending balances   4,650,812    4,635,415 
           
Retained earnings:          
Beginning balances   1,266,987    2,188,917 
Net income (loss)   403,471    (165,306)
Ending balances   1,670,458    2,023,611 
           
Total stockholders' equity, ending balances  $6,321,270   $6,659,026 

 

 
 
 

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)

 
   Three Months Ended March 31,
CASH FLOWS FROM OPERATING ACTIVITIES:  2021  2020
Net income (loss)  $403,471   $(165,306)
Adjustments to reconcile net income (loss) to net cash          
 provided from (used in) operating activities-          
Forgiveness of Paycheck Protection loan (round 1)   (465,097)   —   
   Depreciation and amortization   66,828    97,199 
   Provision for doubtful accounts, net change   —      2,000 
   Provision for inventory obsolescence, net change   —      36,765 
   Deferred taxes, net change   (1,441)   (9,349)
   Reserve for warranty expense, net change   —      1,000 
   Stock based compensation expense related to          
     stock options   17,157    32,111 
Changes in operating assets and liabilities-          
   Accounts receivable   (169,622)   1,201 
   Inventories   (82,022)   (286,797)
   Income taxes receivable   (13,884)   (34,555)
   Prepaid expenses and other   (20,606)   (120,915)
   Accounts payable   21,968    218,563 
   Customer deposits   6,170    (29,699)
   Accrued expenses   (102,547)   28,908 
   Deferred revenue   2,249    (4,539)
           Net cash provided from (used in)          
            operating activities   (337,376)   (233,413)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of property and equipment   —      (9,088)
Patent filing expense   —      (18,772)
           Net cash (used in) investing activities   —      (27,860)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from Paycheck Protection loan (round 2)   471,347    —   
Principal payments made on term loan   (12,006)   (11,391)
           Net cash provided from (used in)          
            financing activities   459,341    (11,391)
           
NET INCREASE (DECREASE) IN CASH   121,965    (272,664)
           
CASH, BEGINNING OF PERIOD   2,195,070    3,185,996 
           
CASH, END OF PERIOD  $2,317,035   $2,913,332 
           
SUPPLEMENTAL INFORMATION:          
Cash paid for interest  $13,246   $13,860 
           
Cash paid for income tax  $—     $20,063